Heart failure.
McKelvie
Robert
R
McMaster University, Hamilton, Ontario, Canada.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017147:Defibrillators, Implantable; D004077:Digoxin / Q000009:adverse effects / Q000627:therapeutic use; D015444:Exercise; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D010348:Patient Care Team; D016032:Randomized Controlled Trials as Topic; D013148:Spironolactone / Q000009:adverse effects / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D013148:Spironolactone; D004077:Digoxin